Dr. Jill Johnsen is a researcher and hematologist at the University of Washington and the Washington Center for Bleeding Disorders. She is the Principal Investigator of the My Life, Our Future Biorepository, and part of the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine Program on behalf of the hemophilia cohorts MLOF and the Hemophilia Inhibitor Previously Untreated Patient Study. She is a physician and scientist who is an expert in coagulation (blood clotting), genetics, and molecular biology. A major focus of her research is using new genetic technologies to address unmet needs in bleeding disorders, with a specific interest in better understanding how bleeding uniquely impacts women. She co-chaired the 2018 NHLBI State of the Science Workshop on Factor VIII Inhibitors, Working Group 4, that developed a national blueprint for pregnancy/birth longitudinal cohorts describing an innovative vision for longitudinal hemophilia research for mothers and babies relevant to the HARP.

Dr. Shannon Meeks is a Professor of Pediatrics at Emory University where she holds the John and Elaine Mitchell Chair in Hemostasis. She is also the Program Director for Hemostasis and Thrombosis within the Aflac Cancer and Blood Disorders Service at Children’s Healthcare of Atlanta. She is a leading physician and scientist who studies the immune response to factor VIII (FVIII), an essential blood-clotting protein, both in laboratory experiments and during the treatment of patients with bleeding disorders. Currently, she is studying the early initiating events in the immune response to FVIII and is an expert in anti-FVIII antibody formation and characterization. She also serves as the President of the Hemostasis and Thrombosis Research Society and leads the administrative core for the National Heart, Lung, and Blood Institute Centers for the Investigation of FVIII Immunogenicity, which means being able to produce an immune response. Her clinical focus as a pediatric hematologist is on the treatment of children, teens, and young adults with bleeding disorders. She has been involved with several clinical trials, including the Hemophilia Inhibitor Previously Untreated Patient Study.